Pluristem Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on January 23, 2009, regarding events occurring on January 21, 2009. The report covers the Annual Meeting of Stockholders for Pluristem Therapeutics Inc., a Nevada corporation headquartered in Haifa, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance.
Material Changes
- Stock Option Plan Amendment: Stockholders approved the Amended and Restated 2005 Stock Option Plan. The number of shares authorized for issuance was increased from 1,990,000 to 16% of the number of shares of Common Stock issued and outstanding on a fully diluted basis immediately prior to the grant of securities.
- Plan Terms: The plan now allows for the issuance of shares of Common Stock and units for such shares. The termination date was set to December 31, 2018.
- Board Elections: Stockholders holding 64% of the Company's voting power participated in the meeting and elected eight directors: Zami Aberman, Israel Ben-Yoram, Isaac Braun, Mark Germain, Hava Meretzki, Nachum Rosman, Doron Shorrer, and Shai Pines.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard corporate actions reported.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding on a fully diluted basis to calculate the new total share pool available under the amended 2005 Stock Option Plan.
- Confirm the terms of the newly elected board members and their tenure until the next annual meeting.
- Review Exhibit 10.1 (Amended and Restated 2005 Stock Option Plan) for specific vesting schedules and grant conditions.